Sinorda Biomedicine, a clinical stage biopharma firm located in Guiyang, Guizhou, China, agreed to collaborate with WuXi Biologics, a China-based CRDMO, on the development and manufacturing of SND006, a bispecific antibody, for the potential treatment of inflammatory bowel disease (IBD) and other autoimmune diseases.
Officials at Sinorda say the company will leverage WuXi Biologics’ experience and manufacturing capabilities in biologics development and manufacturing to focus on advancing Sinorda’s SND006’s preclinical pharmacology studies and clinical supply and accelerating the IND application process. Sinorda reports that it has completed in vitro functional validation studies of SND006 and plans to submit IND applications to both the National Medical Products Administration (NMPA) in China and the FDA this year.
In the future, the two companies expect to further expand their collaboration around Sinorda Biomedicine’s potential pipeline, including multiple integrated projects spanning from molecule discovery to clinical manufacturing.
“Over the past decade, we have accumulated experience across hundreds of projects in bispecific and multispecific antibodies, which have become one of our fastest‑growing areas,” notes Chris Chen, PhD, CEO of WuXi Biologics. “Looking ahead, we will continue accelerating and transforming biologics discovery, development and manufacturing to empower global partners and make innovative biologics more accessible and affordable for patients worldwide.”
“SND006 is a potentially best-in-class innovative bispecific antibody, with the potential to deliver breakthroughs in the treatment of gastrointestinal and multiple autoimmune diseases,” adds Pingsheng Hu, PhD, chairman and general manager of Sinorda. “We believe this collaboration will accelerate the IND filings of our innovative biologics in China and worldwide, address unmet medical needs in autoimmune diseases, and ultimately bring safe and effective therapies to patients.”
